Westchester Capital Management Inc. lowered its holdings in Becton Dickinson and Co (NYSE:BDX) by 0.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 42,884 shares of the medical instruments supplier’s stock after selling 60 shares during the quarter. Becton Dickinson and comprises approximately 4.3% of Westchester Capital Management Inc.’s holdings, making the stock its 10th largest holding. Westchester Capital Management Inc.’s holdings in Becton Dickinson and were worth $10,848,000 as of its most recent filing with the SEC.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of BDX. Brasada Capital Management LP purchased a new stake in Becton Dickinson and during the 3rd quarter worth approximately $569,000. Reilly Herbert Faulkner III grew its position in Becton Dickinson and by 0.8% during the 3rd quarter. Reilly Herbert Faulkner III now owns 23,470 shares of the medical instruments supplier’s stock worth $5,937,000 after purchasing an additional 188 shares during the last quarter. Arthur M. Cohen & Associates LLC grew its position in Becton Dickinson and by 22.3% during the 3rd quarter. Arthur M. Cohen & Associates LLC now owns 1,207 shares of the medical instruments supplier’s stock worth $305,000 after purchasing an additional 220 shares during the last quarter. Papp L Roy & Associates grew its position in Becton Dickinson and by 5.2% during the 3rd quarter. Papp L Roy & Associates now owns 32,577 shares of the medical instruments supplier’s stock worth $8,241,000 after purchasing an additional 1,608 shares during the last quarter. Finally, Delaney Dennis R grew its position in Becton Dickinson and by 117.0% during the 3rd quarter. Delaney Dennis R now owns 2,268 shares of the medical instruments supplier’s stock worth $575,000 after purchasing an additional 1,223 shares during the last quarter. Hedge funds and other institutional investors own 84.29% of the company’s stock.
In related news, EVP Alexandre Conroy sold 9,829 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $255.06, for a total transaction of $2,506,984.74. Following the sale, the executive vice president now directly owns 16,535 shares of the company’s stock, valued at $4,217,417.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vincent A. Forlenza sold 11,532 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the sale, the chief executive officer now directly owns 218,671 shares in the company, valued at $56,937,554.98. The disclosure for this sale can be found here. Insiders sold a total of 32,174 shares of company stock worth $8,354,013 over the last ninety days. Insiders own 0.12% of the company’s stock.
Several analysts have weighed in on BDX shares. Piper Jaffray Companies dropped their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Wells Fargo & Co dropped their target price on shares of Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Wednesday. Morgan Stanley boosted their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 16th. Finally, ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $266.09.
Shares of BDX stock traded up $0.22 during trading hours on Friday, hitting $244.79. The company’s stock had a trading volume of 1,479,428 shares, compared to its average volume of 1,173,922. The company has a 50 day moving average of $251.93 and a 200 day moving average of $246.89. The stock has a market cap of $66.59 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.62 and a beta of 1.09. The company has a current ratio of 1.19, a quick ratio of 0.67 and a debt-to-equity ratio of 0.85. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $264.74.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, beating the consensus estimate of $3.30 by $0.01. The business had revenue of $4.58 billion for the quarter, compared to the consensus estimate of $4.57 billion. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.51%. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.93 EPS. As a group, analysts anticipate that Becton Dickinson and Co will post 12.58 earnings per share for the current fiscal year.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: How to trade on quiet period expirations
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).